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same concentration. They also described morphologically that
vacuoles were smaller when infected cells were treated with
lovastatin compared with untreated cells. However, they did not
use a quantitative method to prove this effect. Our method, in
which we coupled imaging and software analysis, allows quanti-
tative determination of differences in vacuole size and number.
Interestingly, pravastatin did not have any apparent effect in
reducing C. burnetii infection. Pravastatin is hydrophilic and
seems to be less effective than other statins in different models.
4
This could be due to different pharmacokinetic properties com-
pared with other statins
4 and may explain the lack of activity of
pravastatin in our C. burnetii model of infection. In our study,
lovastatin was effective at a concentration achievable in the sera
of patients treated with this drug. This drug does not seem to
interfere with bacterial entry in cells, as internalization by cells
was not different from controls, as also reported for Salmonella
Typhimurium.
5 We hypothesize that lovastatin indirectly reduces
C. burnetii growth by modifying cholesterol-rich vacuoles.
However, a minimal direct effect on bacteria could not even-
tually be eliminated, as the genome of C. burnetii contains some
genes involved in the steroid biosynthesis pathway, especially
that encoding the HMG CoA reductase, available at the KEGG
web site (http://www.genome.jp/dbget-bin/get_pathway?org_name=
cbu&mapno=00100). In vitro studies with statins in association
with doxycycline could be performed in the future to look for a
possible synergistic inhibitory effect on C. burnetii. Because the
inhibitory effect of statins was seen only with pre-incubated cells,
we believe that lovastatin may be effective in prophylaxis. These
ﬁndings need to be conﬁrmed using an animal model
6 and/or
epidemiological case–control study, especially in patients with
chronic Q fever.
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Sir,
We reported the in vitro activity of tigecycline against 148
strains of Acinetobacter spp. from the infectious diseases
research laboratory at Siriraj Hospital, Bangkok, Thailand,
which showed that only 3.4% of the Acinetobacter spp. strains
were considered resistant to tigecycline due to their inhibition
zone diameters (,13 mm) and MICs determined by broth
microdilution (.2 mg/L).
1 The service microbiology laboratory
of our hospital has reported tigecycline disc diffusion suscepti-
bility results for Acinetobacter spp. based on the interpretative
breakpoints proposed by Jones et al.,
2 which indicated that most
clinical isolates of Acinetobacter spp. were not susceptible to
tigecycline. There were several observations on the effect of the
susceptibility test media on the MICs of tigecycline. Hope
et al.
3 found that the MIC of tigecycline was raised in aged
media. Fernandez-Mazarasa et al.
4 reported that high concen-
trations of manganese in Mueller–Hinton agar (MHA) increased
the MIC90 of tigecycline for A. baumannii determined by Etest
from 1 to 4 mg/L. The service microbiology laboratory at Siriraj
Hospital used MHA (Oxoid), whereas the infectious diseases
research laboratory used MHA [Becton–Dickinson (BD)] for
disc diffusion susceptibility for Acinetobacter spp. Therefore, a
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might be due to a difference in the type of MHA.
We performed tigecycline disc diffusion susceptibility for 102
strains of Acinetobacter spp. isolated from different patients.
These isolates were resistant to all b-lactams, aminoglycosides
and ﬂuoroquinolones. In vitro susceptibility of Acinetobacter spp.
to tigecycline was determined by the Kirby–Bauer disc diffusion
method using a paper disc containing 15 mg of tigecycline per
disc (BD, USA). The MHAs were purchased from BD (Thailand)
and Oxoid Company (Thailand), and they were freshly prepared.
The methodology for susceptibility testing was performed by
direct colony suspension according to the guidelines suggested by
the CLSI.
5 Quality control was performed by testing the suscepti-
bility of Escherichia coli ATCC 25922. The susceptibility tests
using both types of MHAs were performed concurrently under
identical conditions. The comparison of tigecycline inhibition
zone diameters on MHA (BD) and MHA (Oxoid) for 102 isolates
of Acinetobacter spp. is shown in Figure 1. The inhibition zone
diameters observed on MHA (Oxoid) were consistently smaller
than those on MHA (BD), with a mean difference of 3.5 mm and
a range from 1 to 6 mm. The inhibition zone diameters on MHA
(Oxoid) and MHA (BD) were signiﬁcantly correlated (r ¼ 0.95,
P, 0.001). The distribution of tigecycline disc diffusion suscep-
tibility for Acinetobacter spp. performed on MHA (BD) and
MHA (Oxoid) is shown in Table 1. The susceptibility of
Acinetobacter spp. to tigecycline using MHA (BD) was 86.2%,
whereas that using MHA (Oxoid) was only 28.5%. We also
measured the content of manganese in both types of MHAs by
atomic absorption and found that the content of manganese in
MHA (Oxoid) was three times more than that in MHA (BD).
Therefore, the discrepancy in inhibition zone diameters between
MHA (Oxoid) and MHA (BD) might be due to a difference in the
manganese content in MHAs. However, there could be other
associated factors for such a discrepancy, and more studies are
required. The aforementioned observations warrant a clinical
study to determine the efﬁcacy of tigecycline for therapy of
Acinetobacter spp. infections in order to consider which type of
MHA is more appropriate for tigecycline disc diffusion suscepti-
bility for Acinetobacter spp. Meanwhile, the results of tigecycline
disc diffusion susceptibility for Acinetobacter spp. in MHA
(Oxoid) should be cautiously reported and interpreted.
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Figure 1. Comparison of tigecycline inhibition zone diameters on MHA (BD) and MHA (Oxoid) for 102 isolates of Acinetobacter spp.
Table 1. Distribution of tigecycline disc diffusion susceptibility
for Acinetobacter spp. performed on MHA (BD) and MHA
(Oxoid)
Inhibition zone diameter (mm) MHA (Oxoid) MHA (BD)
 12 (resistant) 14 (13.7%) 7 (6.9%)
13–15 59 (57.8%) 7 (6.9%)
 16 (susceptible) 29 (28.5%) 88 (86.2%)
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